

Central Lancashire Online Knowledge (CLOK)

Title	Improving the biopharmaceutical attributes of mangiferin using vitamin E-TPGS co-loaded self-assembled phospholipidic nano-mixed micellar systems
Type	Article
URL	https://clock.uclan.ac.uk/21672/
DOI	##doi##
Date	2018
Citation	Singh, Kamalinder orcid iconORCID: 0000-0001-7325-0711, Khurana, Rajneet Kaur, Gaspar, Balan Louis, Welsby, Gail orcid iconORCID: 0000-0001-9901-7627 and Katare, O.P. (2018) Improving the biopharmaceutical attributes of mangiferin using vitamin E-TPGS co-loaded self-assembled phospholipidic nano-mixed micellar systems. Drug Delivery and Translational Research, 8 (3). pp. 617-632. ISSN 2190-393X
Creators	Singh, Kamalinder, Khurana, Rajneet Kaur, Gaspar, Balan Louis, Welsby, Gail and Katare, O.P.

It is advisable to refer to the publisher's version if you intend to cite from the work. ##doi##

For information about Research at UCLan please go to <http://www.uclan.ac.uk/research/>

All outputs in CLOK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the <http://clock.uclan.ac.uk/policies/>



Improving the biopharmaceutical attributes of mangiferin using vitamin E-TPGS co-loaded self-assembled phospholipidic nano-mixed micellar systems

Rajneet Kaur Khurana¹ · Balan Louis Gaspar² · Gail Welsby³ · O. P. Katare¹ · Kamalinder K. Singh³ · Bhupinder Singh^{1,4}

© The Author(s) 2018

Abstract

The current research work encompasses the development, characterization, and evaluation of self-assembled phospholipidic nano-mixed micellar system (SPNMS) of a poorly soluble BCS Class IV xanthone bioactive, mangiferin (Mgf) functionalized with co-delivery of vitamin E TPGS. Systematic optimization using I-optimal design yielded self-assembled phospholipidic nano-micelles with a particle size of < 60 nm and > 80% of drug release in 15 min. The cytotoxicity and cellular uptake studies performed using MCF-7 and MDA-MB-231 cell lines demonstrated greater kill and faster cellular uptake. The ex vivo intestinal permeability revealed higher lymphatic uptake, while in situ perfusion and in vivo pharmacokinetic studies indicated nearly 6.6- and 3.0-folds augmentation in permeability and bioavailability of Mgf. In a nutshell, vitamin E functionalized SPNMS of Mgf improved the biopharmaceutical performance of Mgf in rats for enhanced anticancer potency.

Keywords Breast cancer · Quality by design (QbD) · Mangiferin · Vitamin E TPGS nanomicelles · Self-assembled phospholipidic nano-mixed micellar system (SPNMS) · Pharmacokinetics · Bioavailability · P-gp efflux · Cellular uptake

Introduction

Mangiferin (Mgf), a naturally produced polyphenol molecule possessing four hydroxyl groups, is an efficient antioxidant

for free radical chain termination [1]. Mgf shows potential cytotoxicity effects on cancer cells and may even induce apoptosis by inhibiting and suppressing nuclear factor kappa B (NF-κB) and NF-κB-inducing kinase [2, 3]. Several literature [3, 4] also report Mgf-induced apoptosis, and tumorigenesis through altered gene expression [5–7], especially using Bcl-2 and Bax. Definitive activity of this bioactive phytochemical has also been documented on HL-60 cells programmed cell death, ascribed to suppression of Bcl-xL and XIAP expression and inhibition of the NF-κB pathway [8].

Despite being a very potent antioxidant molecule, Mgf exhibits very low and variable bioavailability (i.e., 1.5 to 5%), owing principally to limited aqueous oral solubility (i.e., 0.1 to 0.3 mg/mL) and poor lipophilicity (i.e., log P of –0.56), extensive P-gp efflux, high first-pass effect, and considerable metabolism by gut Cytochrome P-450 enzymes [9–14]. By virtue of its low aqueous solubility and lipophilicity, Mgf can be safely regarded as a BCS class IV agent.

Owing to the aforementioned challenges [15], several scientists have attempted to enhance the oral bioavailability of Mgf by formulating its solid dispersions [16], β-cyclodextrin complexes [17, 18], phospholipid complexes [19], and spray-

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s13346-018-0498-4>) contains supplementary material, which is available to authorized users.

✉ Kamalinder K. Singh
ksingh1@uclan.ac.uk; profkksingh@gmail.com

✉ Bhupinder Singh
bsbhoop@yahoo.com; bsbhoop@pu.ac.in

¹ University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India

² Department of Histopathology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh 160012, India

³ School of Pharmacy and Biomedical Sciences, Faculty of Clinical and Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, UK

⁴ UGC-Centre of Excellence in Applications of Nanomaterials, Nanoparticles and Nanocomposites (Biomedical Sciences), Panjab University, Chandigarh 160014, India

dried encapsulation [5]. None of the conventional formulations, therefore, is considered to be highly satisfactory in completely surmounting the multifactorial issues of solubility, lipophilicity, and eventually the bioavailability of Mgf. However, the increase of Mgf bioavailability compared to the plain drug has previously been observed with nanostructured lipidic carriers (NLCs) carrying Mgf and Mgf-phospholipid complex [20], indicating safety towards Caco-2 cells with enhanced intestinal permeation parameters. Xiao and associates elucidated the augmentation in in vitro antitumor activity of Mgf conferred by Mgf loaded magnetic polymeric microspheres [21].

The phospholipid systems have lately been explored for enhancing the biopharmaceutical performance and therapeutic efficacy of several bioactives exhibiting poor hydrophilicity and lipophilicity [20]. As phospholipids constitute major part of the bio-membrane, these hold good biocompatibility, while acting as a carrier for delivering drugs across the biological barriers. The amphiphilic nature of phospholipids is documented to enhance solubility and permeability of the drugs, thus improving their oral biopharmaceutical performance [22]. Other stellar merits of phospholipidic formulations include ease of preparation, along with high drug loading capacity and long-term stability. Further, the employed emulgents and co-emulgents lead to complete micellization of the system and thus solubilizing the BCS class IV bioactive, leading eventually to improved absorption potential and thus better bioavailability.

Self-assembled Phospholipidic Nano Mixed Micellar System (SPNMS), in this regard, hold tremendous market potential due to ease in their manufacturing, higher cost-effectiveness, improved efficacy, and higher scalability [23]. This is the first report of its own kind that offers an insight to the use of SPNMS for improving the in vitro breast cancer cytotoxicity and augmenting the biopharmaceutical attributes of Mgf.

Lately, SPNMS have demonstrated considerable potential to enhance the oral bioavailability of anticancer bioactives owing to their ability to circumvent the major hiccups faced by the latter [24–26]. Composed of lipidic constituents, water-insoluble (with HLB < 12; used in 0–20 parts) and water-soluble (with HLB > 12; used in 30–80 parts) emulgents, coemulgents, and cosolvents, these systems are known to produce ultrafine micelles (i.e., < 50 nm in size) in the gastrointestinal (GI) fluids [27]. Hence, SPNMS have been considered as one of the most promising technologies for a vast diversity of drugs [28]. The key feature of such systems is their ability to incorporate drugs exhibiting values of low partition coefficient [29, 30]. Vitamin E D- α -tocopheryl polyethylene glycol 1000 succinate (TPGS) has been widely used as an emulsifier in nanoparticle formulation of anticancer drugs leading to high drug encapsulation and substantially high cellular uptake by cancer [31]. It also has a dual role, one as a bioactive and the other as a P-gp inhibitor that can block the cancer cell action of

pumping drugs outside of cells and can enhance the anticancer effect [32, 33].

Mixture designs are highly recommended in a delivery system with multiple excipients, wherein the characteristics of the finished product usually depend on the proportion of each substance present, but not on each quantity. Also, optimal designs are preferred when the nature of factor-response relationship is either unknown or is obscure [34]. D-optimal designs, based on the principle of minimization of variance and covariance of parameters, require correct model(s) to be postulated, variable space to be defined, and number of design points to be so chosen that determines the model coefficients with maximum possible efficiency [35].

Attempts were, therefore, made in the current studies for improving the drug loading potential, enhancing dissolution rate, and augmenting the oral bioavailability of Mgf employing systematically prepared functional SPNMS with co-delivery of TPGS, and evaluating these extensively for their biopharmaceutical attributes. Further, its anticancer potential and cellular uptake in mammary adenocarcinoma cell lines (MDA-MB-231 and MCF-7) have also been investigated. Also, toxicity of the developed and blank formulations was evaluated by excising out all the vital organs followed by their histopathological examination. The present research article offers an insight to use the functionalized SPNMS for improving the biopharmaceutical attributes of Mgf. In vitro, in situ, and in vivo studies carried out on the formulations proved these nanostructures to be highly superior to the pure bioactive.

Materials and methods

Mgf was obtained from M/s International Association on Mangiferin Research (IAMR), Nanning, Guangxi, China. Vitamin E TPGS and poly(ethylene glycol) 200 (PEG 200) were purchased from M/s Sigma-Aldrich, Chemicals Pvt. Ltd., Mumbai, India. Phospholipid 90G was provided as *ex-gratis* from Lipoid GmbH, Germany. Empty gelatin capsule shells (size 00) were supplied as gift samples by M/s ACG Associated Capsules Pvt. Ltd., Mumbai.

Identifying quality target product profile and critical quality attributes

As the first and foremost step, quality target product profile (QTPP) was embarked upon as the formulation objectives (Supplementary Table 1) to achieve the maximal therapeutic efficacy for enhancing the bioavailability of Mgf. Valid justification(s) were documented for choosing the apt critical quality attributes (CQAs) to subsequently formulate SPNMS of Mgf (Supplementary Table 2), using the systematic approach of Quality by Design (QbD).

Risk assessment studies

Risk assessment studies were performed to identify, analyze, and assess the possible interaction(s) among Mgf, excipients, and other process parameters. Ishikawa fishbone cause-and-affect diagram was constructed and failure mode effect analysis (FMEA) was carried out in order to earmark the critical material attributes (CMAs) and/or critical process parameters (CPPs) for SPNMS of Mgf [36].

Equilibrium solubility studies

Solubility studies for Mgf were carried out for 72 h at 37 ± 1 °C in a water bath by adding an excess amount of drug in various water-soluble emulgents, viz. Acconon CC-6, Cremophor RH40, Cremophor EL, Vitamin E TPGS, Labrafil M1944, Labrasol, Tween 80 and Tween 40. Cosolvents employed included Transcutol HP, PEG 200, and propylene glycol. Aliquots of the filtrate were suitably diluted with methanol and analyzed using the HPTLC method previously reported by the authors at a λ_{max} of 262 nm [37].

Construction of pseudo-ternary phase diagrams

Phase titration studies were conducted on Phospholipid 90G, Vitamin E TPGS (emulgents), and PEG 200 (cosolvent) as the surfactant mixture (Smix; in the ratio 1:0,1:1,2:1, and 3:1) in the varying ratios, ranging from 1 to 9, were titrated with water at 37 °C to attain the maximal emulsification region [38]. Pseudo-ternary diagrams were constructed using the PCP Disso software ver 3.0 (M/s Pune College of Pharmacy, Pune, India).

Preparation of Mgf SPNMS

SPNMS of Mgf (dose equivalent to 30 mg) were prepared by employing the self-assembly method [39]. Mgf was complexed with Phospholipid 90G (1:1) as per the already developed method [20]. Subsequently, addition of vitamin E TPGS and PEG 200 in ethanolic mixture was carried out using magnetic stirrer at room temperature. Afterwards, butylated hydroxyl toluene (BHT) 0.2% w/w of the total lipid was dissolved in the above alcoholic solution. The aqueous phase containing phosphate buffer saline (pH 7.4), sodium metabisulphite (0.5% w/w), and 0.01% of Triton X-100 was poured into the organic phase in a streamlined manner with continuous stirring at 2000 rpm. The dispersion was stirred for 5–10 min after complete addition of the aqueous phase [40, 41].

QbD-based formulation optimization studies

For systematic optimization of Mgf-SPNMS formulations, an I-optimal mixture design matrix was constructed with 16 runs including five replicates, using the Design Expert® software version 9.0.1 (M/s Stat-Ease, Minneapolis, USA) in order to optimize the amounts of CMAs viz. Phospholipid 90G (X1), vitamin E TPGS (X2), and PEG 200 (X3). Various levels of CMAs were deduced from the pseudoternary phase diagrams. Supplementary Table 3 displays the design matrix for all the prepared formulations containing 30 mg of Mgf. All the prepared formulations were evaluated for Q15, %DE, D_{nm} , and T_{emul} as the CQAs.

QbD-enabled data analysis and validation

In order to correlate CMAs with CQAs, multiple linear regression analysis (MLRA) was applied to get the coefficients of polynomial equations employing [35]. Various model parameters like p value, coefficient of correlation (R), and predicted error sum of squares (PRESS) were analyzed. Besides, 3D-response surface and 2-D contour plots were generated to relate CQAs with CMAs. Further, optimum solution was located by numerical optimization using maximization of the desirability function value, close to unity.

Characterization of SPNMS

Self-emulsification time (T_{emul})

A single dose of the prepared Mgf-SPNMS (1 g) was poured drop-wise in 250 mL of 0.1 N HCl, while stirring at 50 rpm, using a USP XXXI Apparatus II (DS 8000, M/s Lab India Instruments, Mumbai, India) at ambient temperature. The emulsification time was assessed visually and medium was observed for self-emulsification in triplicate.

Globule size (D_{nm}) and zeta potential

SPNMS were prepared by dilution (1 mL) in triplicate for D_{nm} and zeta potential analysis employing Zetasizer ZS 90, (M/s Malvern Instruments, Worcestershire, UK [42].

In vitro dissolution studies

The dialysis bag method was employed to study the in vitro release of Mgf from Mgf-SPNMS. Dissolution studies on the SPNMS formulation ($n = 6$), incorporated in hard gelatin capsules, were conducted in 250 mL of 0.01 N HCl containing 0.5% SLS using USP 31 Type II Apparatus, stirred at 50 rpm at ambient temperature. An aliquot of 5 mL each of the dissolution medium was withdrawn periodically, and replaced with fresh medium to maintain the sink conditions; analysis of Mgf

was carried out at a λ_{max} of 262 nm using the HPTLC technique. From the drug release profile, CQAs like drug release in 15 min ($\text{Rel}_{15\text{min}}$), mean dissolution time (MDT), and dissolution efficiency (DE) were calculated.

Transmission electron microscopy (TEM)

The formulation was observed for microscopy by placing it on a copper grid, stained with phosphotungstic solution (1%) for 30 s (JEM-2100 F, M/s Jeol, Tokyo, Japan).

Ex vivo permeation studies

The method has already been elaborated in one of the published works reported previously by our group [43]. The permeation studies were carried out by excising out the small intestine of sacrificed rats, washed with Krebs's Ringer Buffer (KRB). The jejunum portion was everted on a glass rod after ligation with a thread and equilibrated subsequently in thermoregulated KRB solution. An accurately weighed amount of pure Mgf and optimized Mgf SPNMS (30 mg Mgf) were placed in bath medium outside the gut sac. From the gut sac, aliquots of samples (of 1 mL each) were periodically withdrawn and analyzed using HPTLC to discern the percentage of drug permeated in 45 min ($\text{Perm}_{45\text{min}}$).

MCF-7 and MDA-MB-231 cell-based testing

Cell culture

Human breast adenocarcinoma cells (MCF-7) were obtained from the University of Manchester, UK, and MDA-MB-231 cell lines were purchased from the European Collection of Authenticated Cell Cultures (ECACC), Public Health England, Salisbury, England. To grow MCF-7 cell lines, Dulbecco's Modified Eagle's Medium (DMEM, Sigma) and tissue culture flasks were employed (75 cm²) and maintained constantly in an incubator at 37 °C with 5% CO₂. The culture was trypsinized using 1% trypsin, once the cells were 90% confluent. Similarly, to grow MDA-MB-231 cells, L-15 Medium (Leibovitz) was employed at 37 °C without CO₂.

Cell viability assay

The concentration- and time-dependent cell viability assay of Mgf, blank SPNMS, and Mgf SPNMS were assessed on MCF-7 and MDA-MB-231 cell lines using PrestoBlue cell viability reagent (Invitrogen, USA). Briefly, an aliquot of 100 μL of medium containing 1000 cells per well was seeded in 96-well cell culture plates (Costars, Corning Inc., NY, USA) and incubated for a period of 24 h. The medium was replaced with 90 μL of different concentrations (10–1000 nM) of the said formulations. Cells were treated with the

formulations in separate culture plates before incubating for 24, 48, and 72 h at 37 °C on 5% CO₂. Before calculating the fluorescence, 10 μL PrestoBlue was added 1 h before and the culture plates were incubated at the end of respective time interval [39, 44]. Cell viability was determined using fluorescence measurement at excitation and emission wavelengths of 560 and 590 nm, respectively, and expressed as percentage normalized to untreated controlled cells.

Qualitative and quantitative cellular uptake

Investigations for qualitative cellular uptake were conducted by fluorescence microscopy on MCF-7 and MDA-MB-231 cell lines employing Rhodamine 123 (Rh-123) as a tracker dye, loaded in SPNMS [45]. Cells (1×10^5 per well), both for MCF-7 and MDA-MB-231, were plated onto glass cover slips in DMEM and L-15 media, respectively, and allowed to adhere for overnight. Once adhered, the cells were treated with 0.064 μM Rh-123-loaded SPNMS for 15 min to 4 h separately at 37 °C. Pre-warmed PBS was used to wash cells thrice, subsequently fixed for 20 min at room temperature using 4% (v/v) paraformaldehyde. Cells adhering to microscopic slides were washed thrice with PBS prior to mounting with Vectashield®, a mounting medium containing 300 nM of DAPI (4',6-diamidino-2-phenylindole), a fluorescent stain for nucleus staining. Cells were imaged on a modified cell observer imaging system (Zeiss EC Plan-Neofluar $\times 40/1.3$ oil objective). Rh-123 and DAPI were imaged using a GFP/DAPI filter set with Ex/Em wavelength of 450–490 nm/500–550 nm and 335–383 nm/420–470 nm, respectively. Analysis of the images was carried out using the Zeiss ZEN desk imaging software. For quantitative measurement, cells (1×10^5) were seeded in each well of six-well plate and incubated for overnight. Rh-123-loaded SPNMS (100 $\mu\text{g/mL}$) were added to each well of the six-well plate and incubated for different time intervals, in a manner similar to qualitative measurement [44, 46]. After respective time points, medium containing SPNMS was removed and cells were trypsinized and resuspended in PBS for immediate flowcytometry analysis. Rh-123 signals were detected in FL-1 channel of BD FACSaria flowcytometer. A total of 10,000 events were processed and data were analyzed on Flowing version 2.5.1 (PerttuTerho, Turku Centre for Biotechnology, University of Turku, Finland).

P-gp efflux assay

Overexpression of P-gp in MCF-7 and MDA-MB-231 cells is well-documented in literature [47–49]. P-gp efflux pump does not let anticancer drugs to accumulate within the cell by effluxing it time and again, thereby preventing their cytotoxic or apoptotic effects on cancer cells. For evaluating the P-gp efflux, the multi-drug resistance dye efflux

assay kit (Chemicon International, USA) was employed in which the MCF-7 and MDA-MB-231 cells (2.5×10^5) were treated with Rh-123 and DiOC₂ dyes, with or without vinblastine. To assess the inhibitory activity of SPNMS on MDR1 transporters, these were incubated with Rh-123 alone, Rh-123 with SPNMS, and Rh-123 with vinblastine at 37 °C, along with Rh-123 at 4 °C. Likewise, to estimate the potential of the developed SPNMS formulation for blocking the activity of BCRP transporters, DiOC₂ dye was employed. On similar heels, MCF-7 and MDA-MB-231 cells (2.5×10^5) were incubated with DiOC₂ alone, DiOC₂ with SPNMS, and DiOC₂ with vinblastine at 37 °C, along with DiOC₂ at 4 °C. The fluorescence intensity was measured in a TECAN fluorescence microplate reader at an excitation wavelength of 485 nm and an emission wavelength of 530 nm [50].

Animal Studies

Animals

Animal studies were carried out on Sprague Dawley (SD) rats in bred and housed in Central Animal House, Panjab University, Chandigarh, India. Standard housing conditions were maintained and animals were kept on regular solid feed and water ad libitum. The animal experiments were performed in accordance with the recommendations of the committee for the purpose of control and supervision of experiments on animals (CPSCEA), India. The study protocol was approved by the institutional animal ethics committee (IAEC) of Panjab University, Chandigarh (Protocol no. 578/IAEC dated 1/08/2016).

Intestinal permeation study of Mgf: Confocal laser scanning microscopy

Small intestine from the abdominal cavity of SD rats ($n = 3$) was excised after sacrificing the rat and flushed it with 0.9% sodium chloride solution to remove any traces of feces and blood. Rh-123-loaded SPNMS formulation was introduced in the intestine and kept for 2 h [51]. Microm HM 525 U Cryostat, Thermo Fisher Scientific, USA, was employed for the study with a microtome, i.e., a slicer and a freezer. The intestine specimen was placed on a metal tissue disc, embedded in OCT, consisting of polyethylene glycol and polyvinyl alcohol, secured in a chuck, and frozen (-20 to -30 °C) rapidly to slice up to 10- μ m sections. The section was placed on a glass slide mounted with glycerol, covered with a cover slip to capture the image with the confocal microscope (CLSM) (NIKON C2 PLUS, software IVIS Elements AR).

In situ intestinal perfusion

The in situ perfusion studies were performed as per the procedure previously reported in literature [52]. Briefly, unisex SD rats were put on fasting overnight and divided into two groups with three animals per group, viz. plain Mgf and Mgf-SPNMS. Anesthetized animals were slit open at their abdomen and their jejunum was incised at the upper and lower parts for 4 cm to perfuse KRB. An aliquot of perfusate (1 mL each) was withdrawn periodically and the content of Mgf was analyzed using the HPTLC analysis at 262 nm [37]. Various absorption and permeability parameters were calculated as per the details mentioned in Supplementary Section 2A.

In vivo pharmacokinetic studies

In vivo pharmacokinetic studies were conducted by sparse sampling designed experiment. The formulations were administered through oral gavage on two groups of rats ($n = 60$). Within each group, five subgroups were designated ($5 \times 6 = 30$ animals were employed in one group) and from one animal maximum two blood samples were withdrawn during the entire study alternating between left and right eyes. Group I was administered plain Mgf solution and Group II was given Mgf-SPNMS containing Mgf equivalent to 30mg/Kg [39]. The animals were anesthetized employing isoflurane, and the blood (200 μ L) was withdrawn from the retro-orbital plexus of rats at 0.5, 1, 2, 3, 6, 12, 18, 24, and 36 h, in heparin-coated micro-centrifuge tubes.

Further, plasma was harvested by centrifugation at 10,000 rpm (559 g) for 5 min and analyzed for Mgf using the previously reported and validated HPTLC method [37]. The data were analyzed by non-compartmental and compartmental pharmacokinetic modeling approaches using the WinNonlin software, version 5.0 (M/s Thermo Scientific, USA) [53]. Statistical tests like one-way/two-way ANOVA followed by post hoc multiple comparison tests, and Student's independent *t* test has been applied wherever applicable.

Histopathology and hematological studies

A total of 12 SD female rats were divided into four groups, with three animals in each group. Plain Mgf, blank SPNMS, and Mgf-SPNMS (containing an equivalent amount of 30 mg/kg Mgf) were administered three times per week for 4 weeks in total by oral gavage with suitable intubation cannula. Animals of control group were administered normal saline. At the end of the study, the animals were euthanized by isoflurane. All the vital organs were excised, and fixed in 10% formalin for a minimum period of 24 h. Further, the tissues were passed through a cascade of steps like dehydration with

increasing score of ethyl alcohol, clearing in xylol and mounting in molten paraplast at 58–62 °C [54], staining of sections of 5 µm with hematoxylin and eosin stain (H&E), and subsequent observation for any histopathological change(s) vis-à-vis control under a light microscope. The further procedural details of the histopathology are in Supplementary Section 2B.

Further, after anesthetizing the rats, the blood was collected into 10-ml citrate-phosphate-dextrose anticoagulant vacuum tubes (Haematologic Technologies Inc., USA) by cardiac puncture. Harvested blood was centrifuged (2200×g, 10 min at 4 °C), and the plasma and buffy coat were removed by aspiration. The thin smear slide of the blood from each group was observed under light microscopy. The further procedural details of the hematology are in Supplementary Section 2C.

Results and discussion

Risk Assessment Studies

Supplementary Fig. 1 displayed the Ishikawa diagram with the aim to identify CQAs of Mgf-SPNMS, constructed with the help of the Minitab 16 software; FMEA (Supplementary Table 4) was carried out to estimate the risk(s) caused by selected MAs and/or PPs.

Preliminary Screening

The equilibrium solubility studies revealed that among the surfactants, maximum solubilized fraction of Mgf, i.e., 17.64 mg.mL⁻¹, was observed in vitamin E TPGS (Supplementary Fig. 2A). Among the cosolvents, the highest solubility of Mgf was observed in PEG 200 (i.e., 10.23 mg.mL⁻¹) (Supplementary Fig. 2B). For better solubilization of the drug in SPNMS, proper selection of emulgent and cosolvents is quite imperative, and their emulsification properties are based upon the reduction in energy required to emulsify [55]. The cosolvents further help in reduction of interfacial tension and formation of very fine droplets [56]. Further, it was evident from the ternary diagrams that the S_{mix} (3:1) formed a wider nanoemulsion region, as illustrated in Supplementary Fig. 3(A–D).

Factor screening studies

Pareto charts and half-normal plots revealed the effect of MAs/PPs on the studied CQAs (i.e., Rel_{15min} , D_{nm} , and T_{emul}) divulging that vitamin E TPGS (emulgent) and PEG 200 (cosolvent) were highly influential, as their effect was beyond t value and Bonferroni line limits (Supplementary Fig. 4(A–F)). Emulgent was found to exert a notable effect on the Rel_{15min} , D_{nm} , and T_{emul} , while coemulgent and cosolvent had higher influence on D_{nm} , and T_{emul} .

Nevertheless, the other employed factors like type of mixing, stirring speed, stirring time, and temperature were kept as constant for further studies, as these caused only a trifling effect on the studied CQAs.

QbD-based model development and response surface analysis

The MLRA technique was employed to build second-order quadratic model and the coefficients for each of the CQAs [57] (Eq. 1). Excellent fit of the data was quite apparent from high values of coefficient of correlation, ranging between 0.965 and 0.998 ($p < 0.001$ in all the cases).

$$Y = \beta_1 X_1 + \beta_2 X_2 + \beta_3 X_3 + \beta_4 X_1 X_2 + \beta_5 X_1 X_3 + \beta_6 X_2 X_3 + \beta_7 X_1 X_2 X_3 + \beta_8 X_1 X_2 (X_1 - X_2) + \beta_9 X_1 X_3 (X_1 - X_3) + \beta_{10} X_2 X_3 (X_2 - X_3) \quad (1)$$

where, Y is the response variable, β_1 to β_4 are the coefficients of linear model terms, β_5 to β_7 are the coefficients of quadratic model terms, β_8 to β_{10} are the coefficients of cubic model terms with added interaction terms, while X_1 , X_2 , and X_3 represent the factors employed (Supplementary Table 5).

The generated response surface plots helped in inclusive understanding of the impact of CMAs on the studied CQAs. The 3D-response surface plot in Fig. 1a indicates combined influence of all the CMAs, i.e., Phospholipid 90G, vitamin E TPGS, and PEG 200 on the studied CQA, i.e., globule size. A trivial increase in D_{nm} was observed at the high levels of Phospholipid 90G and intermediate levels of vitamin E TPGS, while a decreasing trend was noticed at the high levels of PEG 200. The minimum value for globule size was noticeable at the intermediate to high levels of vitamin E TPGS, and the intermediate levels of PEG 200, respectively. Smaller globule size, as is well-documented, is highly desirable for quicker absorption of drug into the systemic circulation [58].

Figure 1b depicts an umbrella-like 3D-response surface plot, portraying the maximum value of Rel_{15min} at the intermediate levels of Phospholipid 90G, vitamin E TPGS, and PEG 200. The plot shows a sharp rise in Rel_{15min} values at the intermediate levels of PEG 200 and vitamin E TPGS [59], indicating the highest values of Rel_{15min} . Phospholipid 90G showed a negative effect on the release behavior, which could be attributed to its drug solubilization potential.

Figure 1c represents the 3D diagrammatic depiction of the positive influence of intermediate levels of Phospholipid 90G and vitamin E TPGS on the MDT values. However, on




Fig. 1 **a** Cumulative in vitro drug release profile of Mgf from various formulations prepared as per the I-Optimal mixture design. **b** In vitro drug release profile of optimized SPNMS and drug suspension of Mgf, values expressed in mean \pm SD ($n = 6$). **c** Design space overlay plot for optimized SPNMS. **d** TEM images of SPNMS. Time- and dose-dependent

percentage cell viability by different concentrations of Mgf, B-SPNMS (blank SPNMS), and M-SPNMS (Mgf-loaded SPNMS) at **e–f** 24 h, **g–h** 48 h, and **i–j** 72 h in MCF-7 and MDA-MB-231 cell lines. Data shown are mean \pm SD from three independent experiments

increasing levels of PEG 200, the values of MDT exhibited a declining trend. This unraveled a remarkable influence of lipids and surfactant on MDT, while the cosolvent had varying influence from negligible to high.

The 3D-response surface plot (Fig. 1d) exhibits a sharp decline with increase in the concentration of Phospholipid 90G and PEG 200, while vitamin E TPGS shows increase in the values of DE at its high level. Minimum value of DE was observed at the intermediate levels of vitamin E TPGS and PEG 200, and low levels of Phospholipid 90G.

Figure 1e shows negligible influence of all the constituents on the values of T_{emul} , thus delineating the absence of interaction effect among them. At all the levels of the studied constituents, no significant change was observed ($p > 0.05$).

Figure 1f shows that at the lower levels of Phospholipid 90G, Perm_{45min} values were observed to be maximal, followed by decreasing trend with increased levels of vitamin E TPGS. On the contrary, PEG 200 shows declining effect on Perm_{45min} values. A hump-shaped curve in the 3D plot was observed at the intermediate levels of Phospholipid 90 G, indicating high values of Perm_{45min}. This clearly supported

the fact that Phospholipid 90G helps in faster permeation of drug across the GI tract into the systemic circulation.

Figure 1g exhibit declining values of zeta potential at increasing concentrations of Phospholipid 90G and PEG 200, while vitamin E TPGS shows increase in the zeta potential values at higher levels, followed by a dip at the highest levels. Higher values of zeta potential, required for maintaining physical stability of the nanoformulations, were observed at low to intermediate levels of all the constituents.

Characterization of the prepared Mgf SPNMS

Globule size (D_{nm}), zeta potential, and self-emulsification time (T_{emul})

The value of D_{nm} , ranging between 15 and 60 nm, assures the nanomicellar nature of the developed formulations. Emulgents enable to reduce the interfacial tension and stabilize the globules, thus resulting in the formation of smaller globules [60]. Further, nanometric size range of globules can be ascribed to the ability of the cosolvent to facilitate the efficient emulsification and fluidization of the oil-surfactant

blend [61]. Zeta potential was found to range between -20 and -29 mV, indicating the stability of the developed formulation. It is reported in literature that the negative charge in nanomicelles is due to the presence of free fatty acids on oil droplets [62]. T_{emul} values were observed to range within 22 to 64 s. Less values of T_{emul} indicated the tendency of the formulation to emulsify faster in order to produce transparent nanoemulsion [53].

In vitro drug release studies

From the dissolution studies, nearly complete drug release ($> 90\%$) was observed for all formulations resulted within 1 h indicating faster Mgf release from SPNMS (Fig. 2a). The inset in the figure is a clear testimony to more than 80% of Mgf release in 15 min. Also, significant improvement (i.e., about fivefolds) in the dissolution rate was observed vis-à-vis free Mgf suspension ($p < 0.001$) (Fig. 2b). MDT was found to vary between 3 and 18 min, while %DE was found to vary between 22 and 34%.

Permeability studies

Everted gut sac studies indicated that the values of intestinal permeability varied from 59 to 88% for all the developed SPNMS of Mgf. The results are in consonance with literature reports, where the authors also report the increase in membrane permeability with self nano-emulsifying globules [63–65].

Search for the optimum formulation and validation of QbD

Selected CQAs were traded-off to arrive at the optimum formulation and to achieve requisite objectives, i.e., smaller D_{nm} , minimal T_{emul} , highest $\text{Rel}_{15\text{min}}$, and maximum $\text{Perm}_{45\text{min}}$. Therefore, the selection criteria were finalized to search the optimized formulation with $D_{\text{nm}} < 50$ nm, zeta potential < -30 , $T_{\text{emul}} < 1$ min, $\text{Rel}_{15\text{min}} > 80\%$, $\text{DE} > 20\%$, $\text{MDT} > 7$ min, and $\text{Perm}_{45\text{min}} > 70\%$. Numerical desirability methodology was adopted for identifying the optimum formulation, where all the CQAs exhibited the value of desirability function close to unity. Figure 2c portrays the optimized SPNMS of Mgf, demarcated in the design space overlay plot. The optimized formulation contained Phospholipid 90G (312 mg), vitamin E TPGS (294 mg), and PEG 200 (393 mg), with the values of CQAs as D_{nm} of 25 nm, zeta potential of -25 , T_{emul} of 39 s, $\text{Rel}_{15\text{min}}$ of 82%, DE of 26%, MDT of 10, and $\text{Perm}_{45\text{min}}$ 73%, respectively. The TEM analysis of the optimized formulation (Fig. 2d) evidently indicated spherical globules of the SPNMS formed with a mean size of about 15 nm.

Fig. 2 3D-Response surface plots showing the influence of Phospholipid 90G, Vitamin E TPGS, and PEG 200 on the CQAs, viz. **a** Globule size (D_{nm}), **b** percent drug release in 15 min ($\text{Rel}_{15\text{min}}$), **c** mean dissolution time (MDT), **d** dissolution efficiency (DE), **e** emulsification time (T_{emul}), **f** permeability in 45 min ($\text{Perm}_{45\text{min}}$), and **g** zeta potential

Cell line results


Cell viability assay

Various percentage cell viability plots portray that Mgf-SPNMS show the higher toxicity towards MCF-7, suggesting faster onset of action in 24 h, whereas hardly any cell death was observed for MDA-MB-231 cells at the same time-point. Maximum cell death for MDA-MB-231 cells at similar concentration ranges was observed at 72 h. Also, IC_{50} value for MCF-7 cells was found to be 37.56, 22.65, and 4.37 nM at 24, 48, and 72 h, respectively, while negligible cell death was observed at 24 h and a slightly higher IC_{50} , i.e., 52.13 and 45.39 nM, was observed with MDA-MB-231 at 48 and 72 h, respectively (Fig. 2e–j). This could be attributed to the higher accumulation of Mgf-SPNMS in MCF-7 than MDA-MB-231 cells, which is known to express P-gp efflux transporters. The higher expression of P-gp receptors on MDA-MB-231 might be responsible for lower accumulation of Mgf-SPNMS in these cells [66]. Moreover, triple negative MDA-MB-231 cells, which bear an aggressive phenotype, usually respond less favorably to the compounds than the less aggressive, estrogen receptor positive, MCF-7 breast cancer cells [67, 68].

Qualitative and quantitative cellular uptake

On investigating the cellular uptake on MCF-7 and MDA-MB-231 cells, it was observed that Rh-123-SPNMS started migrating within both the cells in 15 min. Qualitative analysis made through the images were processed through Zen Pro 2012, displaying the fluorescent images of Rh-123-SPNMS uptake at various time-points (Fig. 3a, d). The corresponding overlay histograms (Fig. 3b, e), generated after the data were analyzed using the Flowing software, further corroborated the substantial cellular uptake of Rh-123-SPNMS at the same time points, i.e., 15, 30 min, and 1, 2, and 4 h. Through the qualitative and quantitative observations made, intensity of fluorescence was observed to be much higher for MCF-7 cells than for MDA-MB-231 cells ($p < 0.05$) (Fig. 3c, f), suggesting that the SPNMS encountered less hindrance with the former cell lines.

Therefore, one could conclude and correlate the cellular viability and uptake results, in which higher and quicker cellular uptake of the formulation is the indicative of the lower IC_{50} values obtained for both the cell lines. Also, it is reported that the higher cellular uptake of the SPNMS is owing to the presence of surfactants, attributing to the enhancement of the permeability and could change the cell integrity [69, 70].






Fig. 3 **a** and **d** Qualitative analysis indicated the increased cellular uptake with the increase in the Rh-123 intensity for MCF-7 and MDA-MB-231, respectively. **b** and **e** Flow cytometry histogram overlays for MCF-7 and MDA-MB-231 cells of Rh-123 SPNMS following control (untreated

cells), 15 min, 30 min, 1 h, 2 h, and 4 h incubation at 37 °C. **c** and **f** Fluorescence intensity plotted vs. time also corroborated the cellular uptake for MCF-7 and MDA-MB-231, respectively

P-gp efflux assay

The P-gp efflux assay revealed that at 4 °C, there was no evidence of active transport, as the MDR and BCRP transporters were inactive, leading to higher accumulation of dyes inside the cells, as can be clearly evident from the fluorescence intensity (Fig. 4a). On the other hand, incubation at 37 °C showed active efflux of both dyes (Rh-123 and DiOC2); however, in the presence of vinblastine, which blocks both the MRP2 and BCRP transporters, lead eventually to higher fluorescence intensity without any efflux [71]. Relatively less efflux of Rh-123 and DiOC2 in the presence of SPNMS could be attributed to the excipients like vitamin E TPGS [72] and PEG [73, 74], which act as the P-gp efflux inhibitors, which is in total agreement with the literature reports. In this context,

SPNMS would be an adept carrier for delivery of Mg²⁺, which is a P-gp substrate [75], facilitate its accumulation in cancer cells by weakening its P-gp mediated efflux.

Intestinal permeation study of Mg²⁺

Figure 4b shows that Rh-123 dye, of its own, does not permeate through the intestine, as it has a tendency to get effluxed by P-gp receptors. However, using optimized Rh-123 SPNMS (Fig. 4c), the fluorescent microvilli of the intestine were observed, indicating the penetration of the prepared formulation, majorly due to the droplets being formed in the nanometric size range. Consequently, the outcome from the CLSM study corroborates improved intestinal permeation with SPNMS, ostensibly owing




Fig. 3 (continued)

to the formation of nano-micelles and the presence of vitamin E TPGS [72] and PEG to act as P-gp inhibitors [74].

In situ intestinal perfusion studies

These studies explore the absorption and permeation behavior of a drug, when administered as an oral formulation [24]. With SPNMS, enhanced values of absorptivity and permeability parameters of Mgf were observed vis-à-vis pure bioactive. As is evident from Fig. 5a, Mgf SPNMS showed significantly escalation in the values of ($p < 0.001$) absorption number (A_n) by 8.12-fold and 3.54-fold, vis-à-vis pure Mgf alone, and with verapamil, respectively. The amount of drug transferred across the GI tract, where Mgf SPNMS exhibited distinct superiority over free bioactive, indicated enhanced drug absorption characteristics [76].

Verapamil, being a potent P-gp inhibitor, was able to improve the permeation and absorption parameters, but only up to a limited extent [77, 78]. Further, a significant increase ($p < 0.01$) in the values of fraction drug absorbed (F_a) was also observed for Mgf SPNMS (i.e., 4.06-fold), and Mgf administered with verapamil (i.e., 3.64-fold) vis-à-vis pure Mgf.

The aforementioned results indicated notable augmentation in the absorption potential of Mgf SPNMS, ostensibly due to transport of bioactive through lymphatic pathways via circumnavigation of its first-pass effect in the liver [24, 79, 80].

Similarly, in case of permeability parameters, the values of effective permeability (P_{eff}) also showed significant, i.e., nearly 6.56-fold and 2.57-fold improvement with SPNMS of Mgf and Mgf-verapamil ($p < 0.001$ each) vis-à-vis pure Mgf, respectively. Likewise, significant increase ($p < 0.001$) in the corresponding values of wall permeability (P_{wall}) was also observed by about 6.88-fold and 4.11-fold. The greater values of P_{eff} and P_{wall} delineate increase in the permeability and uptake characteristics of the optimized formulation, plausibly ascribed to improved permeability and decreased efflux due to the incorporation of emulsifying excipient in the formulations [81, 82].

In vivo pharmacokinetic studies

Following per oral administration of Mgf SPNMS and pure Mgf, plasma levels were monitored in rat at the designated time-points. Thus, the pharmacokinetic profile (Fig. 5b) shows




Fig. 4 **a** Relatively higher fluorescence intensity index indicates inhibition of MDRI and BCRP transporters maximally by Mgf-SPNMS loaded with Rh-123 and DiOC₂ dye, respectively. **b** Shows no migration of Rh-123 dye into the intestine. **c** Rh-123 loaded SPNMS has migrated to microvilli of intestine, indicating its better absorption. **d** Histopathological findings were examined on comparing with the (a) untreated rat after administering saline solution, (b) plain Mgf, (c) blank SPNMS formulation, and (d) Mgf SPNMS. (1) Kidney (a, b, c, d): glomeruli, tubules, and blood vessels are within normal limits. (2) Heart (a, b, c, d): endocardium, epicardium, and myocardium do not show any significant changes. (3) Pancreas (a, b, c, d): pancreatic acini and islets do not show any significant changes. (4) Brain (a, b, c, d): the meninges, cerebral cortex, white matter, cerebellum, hippocampus, and choroid plexus are

within normal limits. (5) Lung (a, b, c, d): the pleura, parenchyma, and the interstitium do not show any significant changes. (6) Small intestine (a, b, c, d): ileum shows normal villi and the brush borders are maintained. No other significant changes are observed. (7). Large intestine (a, b, c, d): mucosa, submucosa, muscularis propria, and serosa are within normal limits. (8). Spleen (a, b, c, d): the splenic red and white pulp does not show any significant changes and are within normal limits. (9) Liver (a, b, c, d): the portal tracts, central vein, and sinusoids do not show any significant changes. (10) Stomach (a, b, c, d): mucosa, submucosa, muscularis propria, and serosa do not show any significant changes. Pictures of whole blood extracted from rats after various treatments e control, f Mgf, and g Mgf SPNMS

considerable difference in the plasma concentrations for Mgf SPNMS vis-à-vis pure Mgf (dose equivalent to 30 mg/kg [39]) at all the time-points studied ($p < 0.001$). Furthermore, a linear decline in the post- T_{\max} log concentration-time profile showed that the drug profile follows 2-CBM kinetics [19]. Table 1 shows various calculated pharmacokinetic parameters for Mgf and Mgf SPNMS with statistically significant ($p < 0.001$) difference among all the parameters as estimated in rats treated with pure plant bioactive versus its SPNMS formulation.

Nearly 4.22- and 2.96-fold increase in the magnitude of C_{\max} and AUC was noted on comparing with pure drug ($p < 0.001$), respectively. Moreover, there was 2.65-fold reduction in T_{\max} vis-à-vis pure Mgf ($p < 0.001$), thus corroborating quite faster onset of action owing to improvement in absorption rate. Besides, maximal variation was observed in the values of K_a , indicating enhanced oral drug absorption of Mgf SPNMS revealing nearly 3.59-fold increase in K_a over plain Mgf ($p < 0.001$). By and large, the pharmacokinetic




Fig. 5 **a** Percent increase in permeability and absorption parameters of Mgf calculated after administering optimized Mgf SPNMS, Mgf administered with verapamil vis-à-vis pure Mgf. **b** Mean plasma

concentration-time curve of Mgf and Mgf SPNMS equivalent to 30 mg/mL ($n = 6$), respectively; mean value of \pm SD

studies in rats ratified the superiority of the formulated Mgf SPNMS in enhancing oral absorption of Mgf.

In vivo toxicity studies

Figure 4d portrays no histopathological change(s) in all the vital organs, indicating that all the three treatments, i.e., Mgf (Fig. 4d (b)), blank (Fig. 4d (c)), and Mgf SPNMS (Fig. 4d (d)) were found to be quite biosafe as that of control (Fig. 4d (a)). Further, all the treated groups, i.e., Mgf, blank SPNMS, and Mgf-loaded SPNMS showed insignificant ($p > 0.05$) pathological changes vis-a-vis the control group.

The whole blood count analysis revealed that all the three treatments were not significantly ($p > 0.05$) affecting the white blood cells (WBC), red blood cells (RBC), hemoglobin (HGB), hematocrit (HCT), and platelet (PLT) count. Treatments with Mgf, blank SPNMS, and Mgf SPNMS decreased the values of WBC, RBC, HGB, and PLT, but the change was not found to be that profound (Table 2). The slides of the blood sample were prepared and observed under upright light microscope. Results showed no morphological changes in the shape of RBC, when treated with any of the formulation on comparing with the control (Fig. 4e–g). As it is evident from the histopathology studies (Fig. 4d) that the Mgf alone,

blank SPNMS and Mgf SPNMS do not show any sign of toxicity on all the vital organs. The results are in accordance with the literature reports where the blank nanomicelles have shown practically no toxicity [83, 84].

Conclusions

In the current studies, SPNMS of Mgf were systematically and successfully developed, which finally composed of Phospholipid 90G, vitamin E TPGS, and PEG 200. Apart from its surfactant like property, vitamin E TPGS was incorporated in the formulation to prevent any possible oxidation of Mgf, and its level was kept as constant throughout the study.

In this piece of work, in vitro, in situ, and in vivo studies carried out on the formulations proved these nanostructures to be highly superior to pure bioactive. The toxicity studies confirmed that the ingredients employed in the formulations were quite biosafe. Therefore, it can be concluded that SPNMS with high drug pay-load possess tremendous promise to augment oral bioavailability of Mgf and several other agents of BCS class IV marked with poor solubility and permeability characteristics like Mgf.

Table 1 Pharmacokinetic parameters obtained from in vivo plasma level studies in rat following oral administration of Mgf and its SPNMS

Treatment formulations	Pharmacokinetic parameters						
	C_{max} (ng.h ⁻¹)	AUC_{last} (h \times ng.mL ⁻¹)	C_{max}/AUC (h ⁻¹)	K_a (h ⁻¹)	T_{max} (h)	MRT (h)	Cl (mL.h ⁻¹)
Mgf	297.14 \pm 56.36	213.38 \pm 25.13	0.098	0.32 \pm 0.09	3.08 \pm 0.18	8.16 \pm 1.73	2543.44 \pm 453.42
Mgf SPNMS	1254.62 \pm 182.15	8962.15 \pm 357.18	0.017	1.15 \pm 0.25	1.43 \pm 0.24	14.19 \pm 1.65	1245.72 \pm 267.13

All the data represented as mean \pm SD ($n = 3$)

Table 2 Whole blood count parameters obtained from blood of rats following various treatments of Mgf and its SPNMS

Mode	Control Count	Mgf Count	Blank SPNMS Count	Mgf SPNMS Count
WBC	$19.8 \times 10^3/\mu\text{L}$	$16.4 \times 10^3/\mu\text{L}$	$18.7 \times 10^3/\mu\text{L}$	$17.5 \times 10^3/\mu\text{L}$
RBC	$10.78 \times 10^6/\mu\text{L}$	$8.21 \times 10^6/\mu\text{L}$	$9.53 \times 10^6/\mu\text{L}$	$7.48 \times 10^6/\mu\text{L}$
HGB	15.14 g/dL	14.54 g/dL	14.10 g/dL	13.32 g/dL
HCT	45.7%	43.9%	44.9%	42.6%
PLT	AG* $760 \times 10^3/\mu\text{L}$	AG* $589 \times 10^3/\mu\text{L}$	AG* $745 \times 10^3/\mu\text{L}$	AG* $638 \times 10^3/\mu\text{L}$

*All values are mean \pm 3

Acknowledgements The financial grants received from the University Grant Commission (UGC), New Delhi, India, to Ms. Rajneet Kaur Khurana under the RFMS scheme-F. No. 5-94/2007(BSR) is deeply acknowledged. The authors also acknowledge the use of the biomedical facilities of the University of Central Lancashire for cell culture experiments. The authors gratefully acknowledge the generosity of M/s Stat-Ease Inc., Minneapolis, USA, for providing one perpetual license and multiple single annual license of the Design Expert® software, version 9.0.

Compliance with ethical standards

The animal experiments were performed in accordance with the recommendations of the committee for the purpose of control and supervision of experiments on animals (CPSCEA), India. The study protocol was approved by the institutional animal ethics committee (IAEC) of Panjab University, Chandigarh (Protocol no. 578/IAEC dated 1/08/2016).

Conflict of interest The authors declare that they have no conflicts of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

- Mujawdiya PK, Kapur S. Mangiferin: A potential natural molecule for management of metabolic syndrome. *Int J Pharm Pharm Sci*. 2015;7:9–13.
- Takeda T, Tsubaki M, Kino T, Yamagishi M, Iida M, Itoh T, et al. Mangiferin induces apoptosis in multiple myeloma cell lines by suppressing the activation of nuclear factor kappa B-inducing kinase. *Chem Biol Interact*. 2016;251:26–33.
- Shoji K, Tsubaki M, Yamazoe Y, Satou T, Itoh T, Kidera Y, et al. Mangiferin induces apoptosis by suppressing Bcl-xL and XIAP expressions and nuclear entry of NF-kappaB in HL-60 cells. *Arch Pharm Res*. 2011;34(3):469–75.
- Pan LL, Wang AY, Huang YQ, Luo Y, Ling M. Mangiferin induces apoptosis by regulating Bcl-2 and Bax expression in the CNE2 nasopharyngeal carcinoma cell line. *Asian J Cancer Prev*. 2014;15(17):7065–8.
- de Souza JRR, Feitosa JPA, Ricardo NMPS, Trevisan MTS, de Paula HCB, Ulrich CM, et al. Spray-drying encapsulation of mangiferin using natural polymers. *Food Hydrocoll*. 2013;33(1):10–8.
- Yoshimi N, Matsunaga K, Katayama M, Yamada Y, Kuno T, Qiao Z, et al. The inhibitory effects of mangiferin, a naturally occurring glucosylxanthone, in bowel carcinogenesis of male F344 rats. *Cancer Lett*. 2001;163(2):163–70.
- Rajendran P, Ekambaram G, Magesh V, Sakthisekaran D. Chemopreventive efficacy of mangiferin against benzo(a)pyrene induced lung carcinogenesis in experimental animals. *Environ Toxicol Pharmacol*. 2008;26(3):278–82.
- Tsubaki M, Takeda T, Kino T, Itoh T, Imano M, Tanabe G, et al. Mangiferin suppresses CIA by suppressing the expression of TNF- α , IL-6, IL-1 β , and RANKL through inhibiting the activation of NF- κ B and ERK1/2. *Am J Transl Res*. 2015;7(8):1371–81.
- Núñez-Sellés AJ. Antioxidant therapy: myth or reality? *J Braz Chem Soc*. 2005;16(4):699–710.
- Roberts HJ. The mythology of antioxidant therapy. *Tex Heart Inst J*. 2004;31(3):335–6.
- Chem YQ. Mangiferin. 2016; Available from: <http://chemyq.com/En/xz/xz5/45984fmkex.htm>.
- Basheer L, Kerem Z. Interactions between CYP3A4 and dietary polyphenols. *Oxidative Med Cell Longev*. 2015;2015:854015.
- Khurana RK, Kaur R, Lohan S, Singh KK, Singh B. Mangiferin: a promising anticancer bioactive. *Pharm Pat Anal*. 2016;5(3):169–81.
- FoodDB. showing compound mangiferin (FDB012803). 2016.
- Showing compound mangiferin 6'-gallate (FDB018856) (2016. <http://foodb.ca/compounds/FDB018856>).
- Qin L, Yujiang W, Gang D, Zhiping W, Xuejian L, Wanna X, et al. inventors; Guangxi University of Traditional Chinese Medicine, assignee. Multi-element mangiferin solid dispersion as well as preparation method and application thereof China patent CN 104473875 A. 2014.
- da Rocha Ferreira F, Valentim LB, Luís Catari Ramones E, Salles Trevisan MT, Olea-Azar C, Perez-Cruz F, et al. Antioxidant activity of the mangiferin inclusion complex with β -cyclodextrin. *LWT Food Sci Technol*. 2013;51(1):129–34.
- Yang XZY, Chen Y, Liao X, Gao C, Xiao D, Qin Q, et al. Host-guest inclusion system of mangiferin with β -cyclodextrin and its derivatives. *Mater Sci Eng C Mater Biol Appl*. 2013;33(4):2386–91.
- Bhattacharyya S, Ahmmed SM, Saha BP, Mukherjee PK. Soya phospholipid complex of mangiferin enhances its hepatoprotectivity by improving its bioavailability and pharmacokinetics. *J Sci Food Agric*. 2013;94(7):1380–8.
- Khurana RK, Bansal AK, Beg S, Burrow AJ, Katare OP, Singh KK, et al. Enhancing biopharmaceutical attributes of phospholipid complex-loaded nanostructured lipidic carriers of mangiferin: systematic development, characterization and evaluation. *Int J Pharm*. 2017;518(1–2):289–306.

21. Xiao W, Hou J, Ma J, Yu B, Ren J, Jin W, et al. Mangiferin loaded magnetic PCEC microspheres: preparation, characterization and antitumor activity studies in vitro. *Arch Pharm Res.* 2014;30:30.
22. Pichot R, Watson RL, Norton IT. Phospholipids at the interface: current trends and challenges. *Int Mol Sci.* 2013;14(6):11767–94.
23. Singh B, Beg S, Khurana RK, Sandhu PS, Kaur R, Katare OP. Recent advances in self-emulsifying drug delivery systems (SEDDS). *Crit Ther Drug Carrier Syst.* 2014;31(2):121–85.
24. Singh B, Bhandopadhyay S, Kapil R, Singh R, Katare O. Self-emulsifying drug delivery systems (SEDDS): formulation development, characterization, and applications. *Crit Rev Ther Drug Carrier Syst.* 2009;26(5):427–521.
25. Hou J, Sun E, Zhang ZH, Wang J, Yang L, Cui L, et al. Improved oral absorption and anti-lung cancer activity of paclitaxel-loaded mixed micelles. *Drug Deliv.* 2017;24(1):261–9.
26. Zhang D, Kong YY, Sun JH, Huo SJ, Zhou M, Gui YL, et al. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance. *Int J Nanomedicine.* 2017;12:2081–108.
27. Akula S, Gurram AK, Devireddi SR. Evaluation of surfactant effect on self micro emulsifying drug delivery system (SMEDDS) of lercanidipine hydrochloride: formulation and evaluation. *J Pharm Innov.* 2015;10:374–87.
28. Narayana L, Chella N, Kumar D, Shastri NR. Design of a novel type IV lipid-based delivery system for improved delivery of drugs with low partition coefficient. *J Liposome Res.* 2015;25(4):325–33.
29. Pattewar S, Kasture S, Pande V, Sharma S. Self microemulsifying drug delivery system: a lipid based drug delivery system. *Int J Pharm Sci Res.* 2014;7(2):443–52.
30. Sarpal K, Pawar YB, Bansal AK. Self-emulsifying drug delivery systems: a strategy to improve oral bioavailability. *CRIPS.* 2010;11(3):42–9.
31. Gaonkar RH, Ganguly S, Dewanjee S, Sinha S, Gupta A, Chattopadhyay D, et al. Garcinol loaded vitamin E TPGS emulsified PLGA nanoparticles: preparation, physicochemical characterization, in vitro and in vivo studies. *Sci Rep.* 2017;7(1):530.
32. Zhu H, Chen H, Zeng X, Wang Z, Zhang X, Wu Y, et al. Co-delivery of chemotherapeutic drugs with vitamin E TPGS by porous PLGA nanoparticles for enhanced chemotherapy against multi-drug resistance. *Biomaterials.* 2014;35(7):2391–400.
33. Zhao D, Zhang H, Yang S, He W, Luan Y. Redox-sensitive mPEG-SS-PTX/TPGS mixed micelles: an efficient drug delivery system for overcoming multidrug resistance. *Int J Pharm.* 2016;515(1–2):281–92.
34. Singh B, Kapil R, Nandi M, Ahuja N. Developing oral drug delivery systems using formulation by design: vital precepts, retrospect and prospects. *Expert Opin Drug Deliv.* 2011;8(10):1341–60.
35. Singh B, Kaur A, Dhiman S, Garg B, Khurana RK, Beg S. QbD-enabled development of novel stimuli-responsive gastroretentive systems of acyclovir for improved patient compliance and biopharmaceutical performance. *AAPS PharmSciTech.* 2016;17(2):454–65.
36. Sidhaye AA, Bhuran KC, Zambare S, Abubaker M, Nirmalan N, Singh KK. Bio-inspired artemether-loaded human serum albumin nanoparticles for effective control of malaria-infected erythrocytes. *Nanomedicine.* 2016;11:2809–28.
37. Khurana RK, Rao S, Beg S, Katare OP, Singh B. Systematic development and validation of a thin-layer densitometric bioanalytical method for estimation of mangiferin employing analytical quality by design (AQbD) approach. *J Chromatogr Sci.* 2016;54(5):829–41.
38. Singh AK, Chaurasiya A, Awasthi A, Mishra G, Asati D, Khar RK, et al. Oral bioavailability enhancement of exemestane from self-microemulsifying drug delivery system (SMEDDS). *AAPS PharmSciTech.* 2009;10(3):906–16.
39. Bartoszewski R, Hering A, Marszał M, Stefanowicz Hajduk J, Bartoszevska S, Kapoor N, et al. Mangiferin has an additive effect on the apoptotic properties of hesperidin in *Cyclopia* sp. tea extracts. *PLoS One.* 2014;9(3):e92128.
40. Traber MG, Atkinson J. Vitamin E, antioxidant and nothing more. *Free Radic Biol Med.* 2007;43(1):4–15.
41. Sandhu PS, Kumar R, Katare OP, Singh B. Surface-tailored nanomixed micelles containing quercetin-salicylic acid physical complex for enhanced cellular and in vivo activities: a quality by design perspective. *Nanomedicine (Lond).* 2017;12(11):1281–303.
42. Craig DQM, Barker SA, Banning D, Booth SW. An investigation into the mechanisms of self-emulsification using particle size analysis and low frequency dielectric spectroscopy. *Int J Pharm.* 1995;114:103–10.
43. Beg S, Raza K, Kumar R, Chadha R, Katare OP, Singh B. Improved intestinal lymphatic drug targeting via phospholipid complex-loaded nanolipospheres of rosuvastatin calcium. *RSC Adv.* 2016;6:8173–87.
44. Egger AE, Rappel C, Jakupiec MA, Hartinger CG, Heffeter P, Keppler BK. Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. *J Anal At Spectrom.* 2009;24(1):51–61.
45. Martins S, Costa-Lima S, Carneiro T, Cordeiro-da-Silva A, Souto EB, Ferreira DC. Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway. *Int J Pharm.* 2012;430(1–2):216–27.
46. Mei L, Zhang Y, Zheng Y, Tian G, Song C, Yang D, et al. A novel docetaxel-loaded poly (ε-caprolactone)/pluronic F68 nanoparticle overcoming multidrug resistance for breast cancer treatment. *Nanoscale Res Lett.* 2009;4(12):1530–9.
47. Katayama K, Noguchi K, Sugimoto Y. Regulations of P-glycoprotein/ABCB1/MDR1 in human cancer cells. *New J Sci.* 2014:476974.
48. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). *Oncogene.* 2003;22:7340–58.
49. Kapse-Mistry S, Govender T, Srivastava R, Yergeri M. Nanodrug delivery in reversing multidrug resistance in cancer cells. *Front Pharmacol.* 2014;5:159.
50. Khurana RK, Beg S, Burrow AJ, Vashishta RK, Katare OP, Kaur S, et al. Enhancing biopharmaceutical performance of an anticancer drug by long chain PUFA based self-nanoemulsifying lipidic nanomicellar systems. *Eur J Pharm Biopharm.* 2017;121:42–60.
51. Holtfreter MC, Stachs O, Reichard M, Loebermann M, Guthoff RF, Reisinger EC. Confocal laser scanning microscopy for detection of schistosoma mansoni eggs in the gut of mice. *PLoS One.* 2011;6(4):e18799.
52. Bandyopadhyay S, Katare OP, Singh B. Optimized self nano-emulsifying systems of ezetimibe with enhanced bioavailability potential using long chain and medium chain triglycerides. *Colloids Surf B Biointerfaces.* 2012;100:50–61.
53. Beg S, Jena SS, Patra Ch N, Rizwan M, Swain S, Sruti J, et al. Development of solid self-nanoemulsifying granules (SSNEGs) of ondansetron hydrochloride with enhanced bioavailability potential. *Colloids Surf B Biointerfaces.* 2013;101:414–23.
54. El-Sayyad HI, Ismail MF, Shalaby FM, Abou-El-Magd RF, Gaur RL, Fernando A, et al. Histopathological effects of cisplatin, doxorubicin and 5-fluorouracil (5-FU) on the liver of male albino rats. *Int J Biol Sci.* 2009;5(5):466–73.
55. Patel VP, Desai TR, Kapupara PP, Atara SA, Keraliya RA. Self emulsifying drug delivery system: a conventional and alternative approach to improve oral bioavailability of lipophilic drugs. 2010; Available from: <http://www.ijddr.in/drug-development/self-emulsifying-drug-delivery-system-a-conventional-andalternative-approach-to-improve-oral-bioavailability-oflipophilic-drugs.php?aid=5486>.

56. Yadav SK, Parvez N, Sharma PK. An insight to self emulsifying drug delivery systems, their applications and importance in novel drug delivery. *JSIR*. 2014;3(2):273–81.
57. Singh B, Pahuja S, Kapil R, Ahuja N. Formulation development of oral controlled release tablets of hydralazine: optimization of drug release and bioadhesive characteristics. *Acta Pharma*. 2009;59(1):1–13.
58. Sallam MA, Marín Boscá Mí T. Optimization, ex vivo permeation, and stability study of lipid nanocarrier loaded gelatin capsules for treatment of intermittent claudication. *Int J Nanomedicine*. 2015;10:4459–78.
59. Efentakis M, Al-Hmoud H, Buckton G, Rajan Z. The influence of surfactants on drug release from a hydrophobic matrix. *Int J Nanomedicine*. 1991;70:153–8.
60. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. *Biomed Pharmacother*. 2004;58(3):173–82.
61. Gershanik T, Benita S. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. *Eur J Pharm Biopharm*. 2000;50(1):179–88.
62. Patel J, Kevin G, Patel A, Raval M, Sheth N. Design and development of a self-nanoemulsifying drug delivery system for telmisartan for oral drug delivery. *Int J Pharm Investig*. 2011;1(2):112–8.
63. Avachat AM, Patel VG. Self nanoemulsifying drug delivery system of stabilized ellagic acid-phospholipid complex with improved dissolution and permeability. *Saudi Pharm J*. 2015;23(3):276–89.
64. Jeevana JB, Sreelakshmi K. Design and evaluation of self-nanoemulsifying drug delivery system of flutamide. *J Young Pharm*. 2011;3(1):4–8.
65. Kumar A, Jaiswal M. Effect of self nanoemulsifying drug delivery system (SNEDDS) on intestinal permeation and anti-diabetic activity of *Berberis aristata* extract: in-vitro and ex-vivo studies. *J Nanopharm Drug Deliv*. 2016;3:51–62.
66. Uma Suganyaa KS, Govindarajua K, Ganesh Kumara V, Prabhu D, Arulvasu C, Stalin Dhasa T, et al. Anti-proliferative effect of biogenic gold nanoparticles against breast cancer cell lines (MDA-MB-231 & MCF-7). *Appl Surf Sci*. 2016;317:415–24.
67. Ediriweera MK, Tennekoon KH, Samarakoon SR, Thabrew I, Dilip De Silva E. A study of the potential anticancer activity of *Mangifera zeylanica* bark: evaluation of cytotoxic and apoptotic effects of the hexane extract and bioassay-guided fractionation to identify phytochemical constituents. *Oncol Lett*. 2016;11(2):1335–44.
68. VelooKuttya R, Feng SS. Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers. *Biomaterials*. 2013;34:10160–71.
69. Zhang L, Zhu W, Yang C, Guo H, Yu A, Ji J, et al. A novel folate-modified self-microemulsifying drug delivery system of curcumin for colon targeting. *Int J Nanomedicine*. 2012;7:151–62.
70. Sobhani H, Tarighi P, Ostad SN, Shafaati A, Nafissi-Varcheh N, Aboofazeli R. Formulation development and toxicity assessment of triacetin mediated nanoemulsions as novel delivery systems for rapamycin. *Iran J Pharm Res*. 2015;14:3–21.
71. International C. Multidrug resistance direct dye efflux assay; Cat. No. ECM910. USA and Canada 2016.
72. Collnot EM, Baldes C, Schaefer UF, Edgar KJ, Wempe MF, Lehr CM. Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access. *Mol Pharm*. 2010;7(3):642–51.
73. Wang SW, Monagle J, McNulty C, Putnam D, Chen H. Determination of P-glycoprotein inhibition by excipients and their combinations using an integrated high-throughput process. *J Pharm Sci* 2004;93(11):2755–67.
74. Werle M. Natural and synthetic polymers as inhibitors of drug efflux pumps. *Pharm Res*. 2008;25(3):500–11.
75. Louisa M, Soediro TM, Suyatna FD. In vitro modulation of P-glycoprotein, MRP-1 and BCRP expression by mangiferin in doxorubicin-treated MCF-7 cells. *Asian Pac J Cancer Prev* 2014;15(4):1639–42.
76. Madan J, Chawla G, Arora V, Malik R, Bansal AK. Unbiased membrane permeability parameters for gabapentin using boundary layer approach. *AAPS J*. 2005;7(1):E224–30.
77. Karwatsky J, Lincoln MC, Georges E. A mechanism for P-glycoprotein-mediated apoptosis as revealed by verapamil hypersensitivity. *Biochemistry*. 2003;42(42):12163–73.
78. Abdallah HM, Al-Abd AM, El-Dine RS, El-Halawany AM. P-glycoprotein inhibitors of natural origin as potential tumor chemosensitizers: a review. *J Adv Res*. 2014;6(1):45–62.
79. Porter CJ, Charman WN. Intestinal lymphatic drug transport: an update. *Adv Drug Deliv Rev*. 2001;50(1–2):61–80.
80. Singh B, Khurana L, Bandyopadhyay S, Kapil R, Katare OP. Development of optimized self-nano-emulsifying drug delivery systems (SNEDDS) of carvedilol with enhanced bioavailability potential. *Drug Deliv*. 2011;18(8):599–612.
81. Zakeri-Milani P, Valizadeh H, Tajerzadeh H, Azarmi Y, Islambolchilar Z, Barzegar S, et al. Predicting human intestinal permeability using single-pass intestinal perfusion in rat. *J Pharm Pharm Sci*. 2007;10(3):368–79.
82. Song NN, Li QS, Liu CX. Intestinal permeability of metformin using single-pass intestinal perfusion in rats. *World J Gastroenterol*. 2006;12(25):4064–70.
83. Zhang X, Huang Y, Li S. Nanomicellar carriers for targeted delivery of anticancer agents. *Ther Deliv*. 2014;5(1):53–68.
84. Cesur H, Rubinstein I, Pai A, Onyuksel H. Self-associated indisolam in phospholipid-based nanomicelles: a potential nanomedicine for cancer. *Nanomedicine*. 2009;5(2):178–83.